ATE207346T1 - Orale pharmazeutische zusammensetzungen mit sexualhormonen - Google Patents
Orale pharmazeutische zusammensetzungen mit sexualhormonenInfo
- Publication number
- ATE207346T1 ATE207346T1 AT97920854T AT97920854T ATE207346T1 AT E207346 T1 ATE207346 T1 AT E207346T1 AT 97920854 T AT97920854 T AT 97920854T AT 97920854 T AT97920854 T AT 97920854T AT E207346 T1 ATE207346 T1 AT E207346T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- oral pharmaceutical
- surfactant
- propylene glycol
- Prior art date
Links
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 230000001568 sexual effect Effects 0.000 title 1
- 239000004094 surface-active agent Substances 0.000 abstract 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 239000003921 oil Substances 0.000 abstract 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 polyoxyethylene Polymers 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9608719.2A GB9608719D0 (en) | 1996-04-26 | 1996-04-26 | Pharmaceutical compositions |
| PCT/GB1997/001247 WO1997040823A1 (en) | 1996-04-26 | 1997-04-28 | Oral pharmaceutical compositions containing sex hormones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE207346T1 true ATE207346T1 (de) | 2001-11-15 |
Family
ID=10792737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97920854T ATE207346T1 (de) | 1996-04-26 | 1997-04-28 | Orale pharmazeutische zusammensetzungen mit sexualhormonen |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0904064B1 (de) |
| JP (1) | JP5088804B2 (de) |
| KR (1) | KR100511133B1 (de) |
| AT (1) | ATE207346T1 (de) |
| AU (1) | AU2707497A (de) |
| DE (1) | DE69707669T2 (de) |
| DK (1) | DK0904064T3 (de) |
| ES (1) | ES2164339T3 (de) |
| GB (1) | GB9608719D0 (de) |
| PT (1) | PT904064E (de) |
| WO (1) | WO1997040823A1 (de) |
| ZA (1) | ZA973653B (de) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777784B1 (fr) * | 1998-04-27 | 2004-03-19 | Arepa | Composition pharmaceutique a base d'estrogene et de progesterone |
| WO2002085337A1 (en) | 2001-04-20 | 2002-10-31 | The University Of British Columbia | Micellar drug delivery systems for hydrophobic drugs |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| WO2000051570A1 (fr) * | 1999-02-26 | 2000-09-08 | Shionogi & Co., Ltd. | Capsules molles a croquer presentant des proprietes d'administration ameliorees et leur procede de production |
| GB9907715D0 (en) * | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
| RU2246296C2 (ru) * | 1999-04-01 | 2005-02-20 | Акцо Нобель Н.В. | Композиция, включающая ундеканоат тестостерона и касторовое масло |
| US6652880B1 (en) | 1999-04-01 | 2003-11-25 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| HUP0301668A2 (hu) * | 2000-08-10 | 2003-09-29 | Delsys Pharmaceutical Corporation | Hidrofób hatóanyagok javított szilárd adagolási formái |
| FR2818905A1 (fr) * | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
| TNSN03139A1 (fr) | 2001-06-21 | 2005-12-23 | Pfizer Prod Inc | Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle |
| WO2003002095A1 (fr) * | 2001-06-28 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Preparation d'une micro-emulsion de type huile-eau |
| FR2832065B1 (fr) | 2001-11-13 | 2004-11-05 | Besins Int Belgique | Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations |
| JO2505B1 (en) * | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| CN1299686C (zh) * | 2003-04-03 | 2007-02-14 | 上海医药工业研究院 | 黄体酮半固体骨架制剂的组合物 |
| AU2004229165A1 (en) * | 2003-04-17 | 2004-10-28 | Pharmaton S.A. | Multi-vitamin and mineral supplement for pregnant women |
| JP2005047851A (ja) * | 2003-07-29 | 2005-02-24 | Nisshin Pharma Inc | ユビデカレノン含有組成物 |
| ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| WO2006113505A2 (en) * | 2005-04-15 | 2006-10-26 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| CA2664427C (en) | 2006-10-04 | 2012-06-05 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
| EP1961412A1 (de) | 2006-12-27 | 2008-08-27 | LEK Pharmaceuticals D.D. | Selbstmikroemulgierende Arzneimittelabgabesysteme |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| AU2014200332B2 (en) * | 2008-04-28 | 2016-10-06 | Diurnal Limited | Lipid composition |
| WO2010042499A1 (en) | 2008-10-06 | 2010-04-15 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
| KR101702142B1 (ko) * | 2008-10-22 | 2017-02-03 | 아유미 세이야쿠 가부시키가이샤 | 장관 흡수성을 개선하는 의약 조성물 |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| US9011908B2 (en) | 2009-04-06 | 2015-04-21 | Banner Life Sciences Llc | Progesterone solutions for increased bioavailability |
| CN102711741A (zh) * | 2009-11-09 | 2012-10-03 | 比利时胶囊公司 | 递送载体 |
| PL2519230T3 (pl) | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole |
| CN103705462B (zh) * | 2010-04-12 | 2016-08-31 | 克劳拉斯医疗有限公司 | 口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法 |
| SG184540A1 (en) * | 2010-04-12 | 2012-11-29 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US8900631B2 (en) | 2011-04-28 | 2014-12-02 | Health Science Funding, LLC | Dosage form to increase prasterone bioavailability |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9301920B2 (en) * | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| FR2988609B1 (fr) * | 2012-03-30 | 2015-09-04 | Commissariat Energie Atomique | Formulation pour l'hormonotherapie |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| MX393195B (es) | 2012-06-18 | 2025-03-24 | Therapeuticsmd Inc | Capsula de estradiol soluble para insercion por via vaginal |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| FR2997627B1 (fr) | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant de l'ulipristal acetate |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CN105188670B (zh) * | 2013-03-15 | 2018-11-02 | 马留斯医药有限责任公司 | 乳液制剂 |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| EP3157505B1 (de) * | 2014-06-17 | 2019-07-24 | Merck Sharp & Dohme B.V. | Stabile formulierungen von testosteron-undecanoat |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017105512A1 (en) | 2015-12-18 | 2017-06-22 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) * | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| BR112018069877A2 (pt) * | 2016-04-01 | 2019-02-05 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteróide |
| US20170281647A1 (en) * | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| CN111432805B (zh) | 2017-11-27 | 2023-02-17 | 梅克里内科尼蒂翁公司 | 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂 |
| US12150945B2 (en) | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
| WO2020203733A1 (ja) * | 2019-03-29 | 2020-10-08 | 積水化学工業株式会社 | コアシェル構造体、製剤、外用薬、テープ剤及び化粧品 |
| US11564933B2 (en) | 2019-04-12 | 2023-01-31 | Tolmar, Inc. | Methods of treating testosterone deficiency |
| US12403146B2 (en) | 2019-10-30 | 2025-09-02 | Marius Pharmaceuticals, Inc. | Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment |
| CN115052606A (zh) * | 2020-02-05 | 2022-09-13 | 戴尔诺有限公司 | 包含睾酮的药物组合物 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| GB2626266B (en) | 2021-10-08 | 2026-04-08 | Chemo Res S L | Oral pharmaceutical compositions of progesterone and estradiol |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
-
1996
- 1996-04-26 GB GBGB9608719.2A patent/GB9608719D0/en active Pending
-
1997
- 1997-04-25 ZA ZA9703653A patent/ZA973653B/xx unknown
- 1997-04-28 WO PCT/GB1997/001247 patent/WO1997040823A1/en not_active Ceased
- 1997-04-28 DE DE69707669T patent/DE69707669T2/de not_active Expired - Lifetime
- 1997-04-28 PT PT97920854T patent/PT904064E/pt unknown
- 1997-04-28 ES ES97920854T patent/ES2164339T3/es not_active Expired - Lifetime
- 1997-04-28 DK DK97920854T patent/DK0904064T3/da active
- 1997-04-28 JP JP53867897A patent/JP5088804B2/ja not_active Expired - Lifetime
- 1997-04-28 AU AU27074/97A patent/AU2707497A/en not_active Abandoned
- 1997-04-28 EP EP97920854A patent/EP0904064B1/de not_active Expired - Lifetime
- 1997-04-28 KR KR1019980708569A patent/KR100511133B1/ko not_active Expired - Lifetime
- 1997-04-28 AT AT97920854T patent/ATE207346T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| KR100511133B1 (ko) | 2006-04-28 |
| JP5088804B2 (ja) | 2012-12-05 |
| EP0904064B1 (de) | 2001-10-24 |
| DE69707669D1 (de) | 2001-11-29 |
| GB9608719D0 (en) | 1996-07-03 |
| ZA973653B (en) | 1997-11-19 |
| KR20000065025A (ko) | 2000-11-06 |
| PT904064E (pt) | 2002-02-28 |
| EP0904064A1 (de) | 1999-03-31 |
| AU2707497A (en) | 1997-11-19 |
| DK0904064T3 (da) | 2001-12-17 |
| ES2164339T3 (es) | 2002-02-16 |
| DE69707669T2 (de) | 2002-07-11 |
| WO1997040823A1 (en) | 1997-11-06 |
| JP2000510458A (ja) | 2000-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69707669D1 (de) | Orale pharmazeutische zusammensetzungen mit sexualhormonen | |
| US5532002A (en) | Gelatin pharmaceutical formulations | |
| US5738871A (en) | Pharmaceutical formulations | |
| NO20014719D0 (no) | Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler | |
| KR100666016B1 (ko) | 테스토스테론 운데카노에이트 및 피마자유를 포함하는 제제 | |
| KR940018091A (ko) | 불포화 지방산을 포함하는 처방 | |
| ES2195175T3 (es) | Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico. | |
| CN101528196A (zh) | 用于生物利用性差的药物的自乳化组合物 | |
| PT1152755E (pt) | Acidos gordos essenciais destinados a prevencao de acidentes cardio-vasculares | |
| ES2168271T3 (es) | Composiciones farmaceuticas que contienen ciclosporinas. | |
| ES2101574T3 (es) | Composicion administrable por via oral apta para formar una microemulsion. | |
| KR970704433A (ko) | 의약 조성물로서의 DHA의 용도(Use of DHA as a pharmaceutical composition) | |
| AR029615A1 (es) | Una formulacion farmaceutica para la administracion oral | |
| UY26303A1 (es) | Composiciones farmacéuticas para administración oral y tópica | |
| GR3035613T3 (en) | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids | |
| ES2180065T3 (es) | Formulaciones de uso topico que contienen acetato de vitamina e. | |
| KR930005635A (ko) | 약제학적 조성물 | |
| CA2222161A1 (en) | Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories | |
| MY130474A (en) | Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants | |
| NZ506579A (en) | Palatable oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors | |
| JP2000159660A (ja) | シクロスポリンカプセル剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |